• Andera Partners led a USD 20 million Series D financing in Rivermark Medical, a urology-focused medical device company developing FloStent, a non-surgical, fully reversible implant for men with lower urinary tract symptoms linked to benign prostatic hyperplasia.
• Round included existing investors, with participation from an unnamed strategic investor.
• Proceeds earmarked to fund RAPID III pivotal clinical trial, support US regulatory approval, prepare for commercial launch of FloStent.
• Financing follows positive multicenter results from RAPID II, which showed rapid recovery with durable effect through 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Andera Partners SAS published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.